Posted inAllergy & Immunology news Respiratory
Rademikibart and Eosinophil Counts in Moderate-to-Severe Asthma: Insights from a Phase 2b Randomized Trial
This article reviews exploratory analyses from a phase 2b trial examining eosinophil count changes in adults with uncontrolled moderate-to-severe asthma treated with the IL-4Rα inhibitor rademikibart, indicating a low risk of treatment-emergent hypereosinophilia.